Anti-CTLA-4 (Tremelimumab), Human IgG2 Antibody

(No reviews yet) Write a Review
SKU:
A2163-100
£332.93
Frequently bought together:

Description

Anti-CTLA-4 (Tremelimumab), Human IgG2 Antibodyis available at Gentaur for Next week Delivery.

Description: The research-grade biosimilar is a fully-humanized IgG2 monoclonal antibody that binds to human cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) expressed on the activated T cells. Binding to CTLA-4 results in inhibition of its association with the ligands B7-1 (CD80) and B7-2 (CD86), thereby preventing the downregulation of T-cell activation and inhibition of tumor growth. The original drug is currently undergoing clinical trials for the treatment of several cancers such as melanoma, mesothelioma and non-small cell lung cancer

Immunogen Sequence:Human CTLA-4

Target Alternative Name:CP-675, CP-675,206, CP-675206 clone 11.2.1, CD; GSE; GRD4; ALPS5; CD152; CTLA4; IDDM12; CELIAC3

Species Reactivities:Human

Tag Line:The biosimilar is a human monoclonal antibody that targets CTLA-4 on activated T-lymphocytes and inhibits the interaction with its ligands CD80 and CD86 and promotes T-cell activation

Formulation:In PBS, pH 7.5

Purification: Protein A purified

Application:/

Positive Control:/

Application And Usages:/

Handling:The antibody solution should be gently mixed before use.

View AllClose

Additional Information

Size:
100 µg
Antibody Target:
CTLA-4
Category:
Biosimilars
Host:
Recombinant
Antibody Type:
Monoclonal
Isotype:
IgG2, kappa
Accession Number:
DB11771
Concentration:
1 mg/ml
Appearance:
Colorless liquid
Form:
Liquid
Storage Condition:
-80ºC
Shipping Condition:
Gel Pack
Shelf Life:
12 months
Country of Animal Origin:
USA
Country of Manufacture:
USA
Usage:
For Research Use Only! Not to be used in humans.
Western Blot Verified:
FAUX
Immunocytochemistry Verified:
FAUX
Immunofluorescence Verified:
FAUX
Immunoprecipitation Verified:
FAUX
FACS Verified:
FAUX
ELISA Verified:
FAUX
ChIP Verified:
FAUX
Dot Blot Verified:
FAUX
Flow Cytometry Verified:
FAUX
View AllClose

0 Reviews

View AllClose